Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment
Anthracyclines are the cornerstone of treatment for many malignancies. However, anthracycline cardiotoxicity is a considerable concern given that i…
Category: Cardiomyopathies
Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with pathogenic variants found in about a third of cases. Large…
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality with both monogenic and polygenic components. Here, we report re…
Pediatric hypertrophic cardiomyopathy caused by a novel TNNI3 variant
TNNI3 is a gene that causes hypertrophic cardiomyopathy (HCM). A 14-year-old girl who was diagnosed with nonobstructive HCM presented with c…
Four cardiomyopathy patients with a heterozygous DSG2 p.Arg119Ter variant
DSG2, encoding desmoglein-2, is one of the causative genes of arrhythmogenic cardiomyopathy. We previously identified a homozygous DSG2